| Literature DB >> 30590011 |
Fen Xie1, Xiaoya Gao1, Wanlin Yang1, Zihan Chang1, Xiaohua Yang1, Xiaobo Wei1, Zifeng Huang1, Huifang Xie1, Zhenyu Yue2, Fengli Zhou3, Qing Wang1.
Abstract
Parkinson's disease (PD) is the second most common neurodegenerative disease in the world. With the advent of an aging population and improving life expectancy worldwide, the number of PD patients is expected to increase, which may lead to an urgent need for effective preventive and diagnostic strategies for PD. Although there is increasing research regarding the pathogenesis of PD, there is limited knowledge regarding the prevention of PD. Moreover, the diagnosis of PD depends on clinical criteria, which require the occurrence of bradykinesia and at least one symptom of rest tremor or rigidity. However, converging evidence from clinical, genetic, neuropathological, and imaging studies suggests the initiation of PD-specific pathology prior to the initial presentation of these classical motor clinical features by years or decades. This latent stage of neurodegeneration in PD is a particularly important stage for effective neuroprotective therapies, which might retard the progression or prevent the onset of PD. Therefore, the exploration of risk factors and premotor biomarkers is not only crucial to the early diagnosis of PD but is also helpful in the development of effective neuroprotection and health care strategies for appropriate populations at risk for PD. In this review, we searched and summarized ∼249 researches and 31 reviews focusing on the risk factors and prodromal biomarkers of PD and published in MEDLINE.Entities:
Keywords: Biomarkers; Early diagnosis; PD; Prodromal stage; Risk factors
Mesh:
Substances:
Year: 2019 PMID: 30590011 DOI: 10.1021/acschemneuro.8b00520
Source DB: PubMed Journal: ACS Chem Neurosci ISSN: 1948-7193 Impact factor: 4.418